Pafolacianine | CAS# 1628423-76-6 (free base) | Folate receptor-directing imaging agent

MedKoo Cat#: 463874 | Name: Pafolacianine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pafolacianine, also known as OTL0038 and OTL-38, is a folate receptor-directing imaging agent. OTL0038 accumulated at sites of inflammation in animal models. OTL-0038 displays high affinity and specificity for FRs and was shown (i) to accumulate in vivo in tumor cells expressing FRs, and (ii) to be non-toxic in mice at clinical dose x 1000. OTL0038 has the ability to predict responses to multiple therapies in four murine models of inflammation. Pafolacianine was approved to identify ovarian cancer lesions.

Chemical Structure

Pafolacianine

CAS#1628423-76-6 (free acid)

Theoretical Analysis

MedKoo Cat#: 463874

Name: Pafolacianine

CAS#: 1628423-76-6 (free acid)

Chemical Formula: C61H67N9O17S4

Exact Mass: 1325.3538

Molecular Weight: 1326.49

Elemental Analysis: C, 55.23; H, 5.09; N, 9.50; O, 20.50; S, 9.67

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 2,650.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1628858-03-6 (sodium) 1628423-76-6 (free acid)

Synonym

Pafolacianine; OTL0038; OTL 0038; OTL-0038; OTL38; OTL-38; OTL 38; Cytalux;

IUPAC/Chemical Name

hydrogen (S)-2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-3-(4-(((E)-2-((E)-2-(3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)-3H-indol-1-ium-2-yl)vinyl)-6-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)oxy)phenyl)propanoate

InChi Key

PDXNSXLPXJFETD-UHFFFAOYSA-N

InChi Code

InChI=1S/C61H67N9O17S4/c1-60(2)46-33-44(90(81,82)83)22-24-49(46)69(28-5-7-30-88(75,76)77)51(60)26-16-38-10-9-11-39(17-27-52-61(3,4)47-34-45(91(84,85)86)23-25-50(47)70(52)29-6-8-31-89(78,79)80)54(38)87-43-20-12-37(13-21-43)32-48(58(73)74)66-56(71)40-14-18-41(19-15-40)63-35-42-36-64-55-53(65-42)57(72)68-59(62)67-55/h12-27,33-34,36,48H,5-11,28-32,35H2,1-4H3,(H9-,62,63,64,66,67,68,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86)

SMILES Code

NC(N1)=NC(N=CC(CNC2=CC=C(C(N[C@]([H])(C([O-])=O)CC3=CC=C(OC4=C(/C=C/C5=[N+](CCCCS(=O)([O-])=O)C6=C(C=C(S(=O)([O-])=O)C=C6)C5(C)C)CCC/C4=C\C=C7N(CCCCS(=O)([O-])=O)C(C=CC(S(=O)([O-])=O)=C8)=C8C\7(C)C)C=C3)=O)C=C2)=N9)=C9C1=O.[H+].[H+].[H+].[H+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,326.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Muynck LDAN, Gaarenstroom KN, Sier CFM, Duijvenvoorde MV, Bosse T, Mieog JSD, Kroon CD, Vahrmeijer AL, Peters ITA. Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases. Cancers (Basel). 2020 Jun 12;12(6):1562. doi: 10.3390/cancers12061562. PMID: 32545676; PMCID: PMC7352913. 2: Boogerd LSF, Hoogstins CES, Gaarenstroom KN, de Kroon CD, Beltman JJ, Bosse T, Stelloo E, Vuyk J, Low PS, Burggraaf J, Vahrmeijer AL. Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. Oncotarget. 2017 Dec 11;9(1):791-801. doi: 10.18632/oncotarget.23155. PMID: 29416655; PMCID: PMC5787511. 3: Bahler CD, Maniar V, Marley KN, Kheyfets SV, Shum CF, Sundaram CP. OTL-38-Guided Fluorescent Imaging in Renal Cell Cancer Robotic Partial Nephrectomy. J Endourol B Videourol. 2017 Feb 6;31(3):vid.2016.0068. doi: 10.1089/vid.2016.0068. PMID: 32292641; PMCID: PMC6964242. 4: Keating JJ, Runge JJ, Singhal S, Nims S, Venegas O, Durham AC, Swain G, Nie S, Low PS, Holt DE. Intraoperative near-infrared fluorescence imaging targeting folate receptors identifies lung cancer in a large-animal model. Cancer. 2017 May 15;123(6):1051-1060. doi: 10.1002/cncr.30419. Epub 2016 Nov 7. PMID: 28263385; PMCID: PMC5341137. 5: Winum JY. Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors: a patent evaluation of US20160011199A1. Expert Opin Ther Pat. 2016 Nov;26(11):1223-1226. doi: 10.1080/13543776.2016.1241238. Epub 2016 Oct 4. PMID: 27685539. 6: Kelderhouse LE, Mahalingam S, Low PS. Predicting Response to Therapy for Autoimmune and Inflammatory Diseases Using a Folate Receptor-Targeted Near- Infrared Fluorescent Imaging Agent. Mol Imaging Biol. 2016 Apr;18(2):201-8. doi: 10.1007/s11307-015-0876-y. PMID: 26242480.